Holen Sie sich die Stockscreener-App
29.59
4.37%
1.24
Handel nachbörslich:
29.59
Schlusskurs vom Vortag:
$28.35
Offen:
$28.78
24-Stunden-Volumen:
726.22K
Relative Volume:
0.71
Marktkapitalisierung:
$1.73B
Einnahmen:
$54.03M
Nettoeinkommen (Verlust:
$-412.78M
KGV:
-4.1565
EPS:
-7.1189
Netto-Cashflow:
$-377.29M
1W Leistung:
+5.19%
1M Leistung:
-1.23%
6M Leistung:
-19.18%
1J Leistung:
-3.80%
1-Tages-Spanne:
$28.59
$30.16
1-Wochen-Bereich:
$27.40
$30.16
52-Wochen-Spanne:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
29.59 | 1.66B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - marketscreener.com
Agios Pharmaceuticals stock declines 23% in 6 months: Here's why - MSN
The Gross Law Firm Announces an Investigation on Behalf of Agios Pharmaceuticals, Inc. (AGIO) Shareholders Who May Have Been Affected by Fraud - PR Newswire
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
AGIO PE Ratio & Valuation, Is AGIO Overvalued - Intellectia AI
AGIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Agios falls as Leerink cites deaths linked to lead asset Pyrukynd - MSN
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates - MSN
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios P - GuruFocus
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart.com
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - Yahoo Finance
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - marketscreener.com
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gro - GuruFocus
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation - PR Newswire
Liquidity Mapping Around (AGIO) Price Events - Stock Traders Daily
HighVista Strategies LLC Buys 125,171 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does UAE Thalassemia Approval for PYRUKYND Reframe the Bull Case for Agios Pharmaceuticals (AGIO)? - simplywall.st
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen - MarketBeat
Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026 - Meyka
AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Agios Pharmaceuticals (AGIO) price target decreased by 34.97% to 32.77 - MSN
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND Approval And GCC Expansion - simplywall.st
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - Morningstar
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law ViolationsContact The Gross Law Firm for Details- AGIO - lelezard.com
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Sec - GuruFocus
Agios Pharmaceuticals (AGIO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Agios (NASDAQ: AGIO) executive sells 2,959 shares to cover RSU tax - Stock Titan
Agios Pharmaceuticals: Worthy Of Accumulation (NASDAQ:AGIO) - Seeking Alpha
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides - AOL.com
Zacks Research Analysts Lift Earnings Estimates for AGIO - MarketBeat
Stock Analysis: Is Agios Pharmaceuticals Inc. stock showing strong momentum2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
AGIO Earnings History & Surprises | EPS & Revenue Results | AGIOS PHARMACEUTICALS INC (NASDAQ:AGIO) - ChartMill
Why Agios Pharmaceuticals Inc. stock could benefit from AI revolutionShort Setup & Risk Managed Investment Entry Signals - Naître et grandir
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
FY2028 Earnings Forecast for AGIO Issued By Zacks Research - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why (AGIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell Alert: Washburn Theodore James Jr. Sells Shares of Agios Pharmaceuticals Inc (AGIO) - GuruFocus
AGIO: Citigroup Raises Price Target Amidst Continuous Buy Ratings | AGIO Stock News - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharmaceuticals (AGIO) Target Price Raised by Citi - GuruFocus
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO – Company AnnouncementFT.com - Financial Times
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by TD Asset Management Inc - MarketBeat
Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug - simplywall.st
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact The Gross Law Firm Regarding Potential Securities Law ViolationsAGIO - StreetInsider
Agios (AGIO) CMO logs tax-driven share sales and major new equity awards - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives large equity grants, sells shares for tax withholding - Stock Titan
AGIOS (AGIO) legal chief gains RSUs, options and sells shares for taxes - Stock Titan
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):